[1]李全双,邓演超,吴 燕,等.初诊2型糖尿病患者综合干预后血栓前状态分子标志物的变化[J].现代检验医学杂志,2015,30(02):36-38.[doi:10.3969/j.issn.1671-7414.2015.02.011]
点击复制

初诊2型糖尿病患者综合干预后血栓前状态分子标志物的变化()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年02期
页码:
36-38
栏目:
论著
出版日期:
2015-03-20

文章信息/Info

作者:
李全双; 邓演超; 吴 燕; 程 星
徐州市医学科学研究所,徐州市中心医院,徐州市糖尿病研究所,江苏徐州 221006
关键词:
2型糖尿病;  血栓前状态;  综合干预
分类号:
R587.1; R392.11
DOI:
10.3969/j.issn.1671-7414.2015.02.011
文献标志码:
A
摘要:
目的 探讨初诊2型糖尿病(T2DM)患者经综合干预后血栓前状态分子标志物的变化。方法 在2013年选择60例初诊T2DM患者,按照饮食干预、运动指导、药物治疗、疾病监测和糖尿病教育五项措施实施12个月的综合干预。干预前、干预6个月和干预12个月分别采血样,检测血糖(Glu)、糖化血红蛋白(HbA1c)等生化项目,分离血浆-70℃保存,统一检测血栓分子标志物:内皮素-1(ET-1),血栓素B2(TXB2),凝血酶-抗凝血酶复合物(TAT)和D-二聚体(DD)。按照用药途径把T2DM患者分为胰岛素治疗组与口服药物治疗组,进行干预前后比较。以60例体检健康者为正常对照组,数据使用spss13.0统计软件分析。结果 60例T2DM患者Glu,HbA1c,ET-1,TXB2,TAT和DD干预前的检测值分别是8.86±1.03 mmol/L,8.70%±0.8%,54.8±12.5 ng/L,145±26 ng/L,2.03±0.52 μg/L和0.24±0.08 mg/L; 干预6个月的值分别是5.70±0.56 mmol/L,5.7%±0.6%,54.2±11.7 ng/L,135±24 ng/L,1.81±0.53 μg/L和0.21±0.08 mg/L,干预12个月的值分别是5.78±0.51 mmol/L,5.8%±0.5%,53.9±10.9ng/L,136±24 ng/L,1.82±0.54 μg/L和0.21±0.08 mg/L; 正常对照组检测值分别是5.15±0.34 mmol/L,5.1%±0.3%,53.2±10.6 ng/L,131±25 ng/L,1.79±0.52 μg/L和0.20±0.07 mg/L,四组经方差分析比较,Glu,HbA1c,ET-1,TXB2,TAT和DD的F值分别是449.7,511.2,0.214,3.640,2.750,2.794; P值分别为0.000,0.000,0.887,0.013,0.043,0.041。与对照组和干预后比较,干预前Glu,HbA1c,TXB2,TAT,DD均高于对照组,差异均有统计学意义(P<0.05); 而各组间ET-1结果差异无统计学意义(P>0.05)。胰岛素治疗组与口服药物治疗组在干预前后结果比较,ET-1,TXB2,TAT和DD差异无统计学意义(P值均>0.05)。结论 初诊T2DM患者存在血栓前状态,经综合干预后,能改善患者的血栓倾向。

参考文献/References:

[1] 中华医学会糖尿病分会.中国2型糖尿病防治指南[S].北京:北京大学医学出版社,2013. CMA Diabetes Society.China Guideling for Type 2 Diabetes[S].Beijing:Beijing Medical University Press,2013.
[2] 陈艳秋,孙建琴,孙 皎,等.综合干预对2型糖尿病控制作用的研究[J].中华内分泌代谢杂志,2010,26(3):199-202. Chen YQ,Sun JQ,Sun J,et al.Integrated intervention in managementof type 2 diabetes[J].Chinese Journal of Endocrinology and Metabolism,2010,26(3):199-202.
[3] 顾梅榴,朱秀国,徐先锋,等.上海市社区2型糖尿病患者综合干预的研究[J].中国全科医学,2012,15(1):107-109. Gu ML,Zhu XG,Xu XF,et al.The study of comprehensive interventionfor patients with type 2 diabetes in community of shanghai[J].Chinese Geneeral Practice,2012,15(1A):107-109.
[4] 邢 辉,王 帆.血小板参数及纤溶系统在2型糖尿病患者中的变化[J].现代检验医学杂志,2009,24(4):142-144. Xing H,Wang F.Variation of the blood platelet and plasminogen activator inhibitor type 1 and tissue-type plasiminogen activator in patients withtype 2 diabetes mellitus[J].Journal of Modern Laboratory Medicine,2009,24(4):142-144.
[5] 齐杰玉,赵 华,郭占军.2型糖尿病患者血液中多种分子水平变化及临床意义[J].广东医学,2009,30(8):1163-1165. Qi JY,Zhao H,Guo ZJ.The variation of various molecular blood levels in patients with type 2diabetes and its clinical significance[J].GuangdongMedical Journal,2009,30(8):1163-1165.
[6] 叶跃红,李兴禄.血栓前状态实验室诊断指标研究[J].重庆医学,2005,34(3):367-368. Ye YH,Li XL.Study of laboratoary markers on prethrombotic state[J].Chongqing Medical Journal,2005,34(3):367-368.
[7] 韩 华,任建民,刘云风.2型糖尿病微血管病变与血浆AT-II,ET,TXB2,6-Keto-PGF1a的相关性[J].山东医药,2009,49(25):80-81. Han H,Ren JM,Liu YF.The correlation between type 2 diabetic microangiopathy and plasma AT-Ⅱ,ET,TXB2,6-Keto-PGF1a[J].Shandong Medical Journal,2009,49(25):80-81.
[8] 古丽娜孜·那比尔,王宝兰,哈木拉提·吾甫尔.2型糖尿病患者血栓前状态的变化及临床价值[J].中国糖尿病杂志,2012,20(5):360-362. Gulinaz·Nabi,Wang BL,Halmurat·Hupur.Changes and their clinicalsignificance of prethrombotic state in patients with type 2 diabetes[J].Chinese Journal of Diabetes,2012,20(5):360-362.

相似文献/References:

[1]张曙晴a,李洪彬b,张骆军a,等.2型糖尿病患者糖化血红蛋白水平与胰岛素分泌及胰岛素抵抗的关系[J].现代检验医学杂志,2016,31(02):108.[doi:10.3969/j.issn.1671-7414.2016.02.032]
　ZHANG Shu-qinga,LI Hong-binb,ZHANG Luo-juna,et al.Correlation between Insulin Secretion,Insulin Resistance and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetic[J].Journal of Modern Laboratory Medicine,2016,31(02):108.[doi:10.3969/j.issn.1671-7414.2016.02.032]
[2]蔡加炉,王 成,汪俊军.循环微小核糖核酸与2型糖尿病的关系[J].现代检验医学杂志,2015,30(03):5.[doi:10.3969/j.issn.1671-7414.2015.03.002]
　CAI Jia-lu,WANG Cheng,WANG Jun-jun.Relationship between Circulating miRNA and Type 2 Diabetes[J].Journal of Modern Laboratory Medicine,2015,30(02):5.[doi:10.3969/j.issn.1671-7414.2015.03.002]
[3]段发兰a,李亚新b,杨飞翔a,等.2型糖尿病患者血清铁代谢相关指标检测意义[J].现代检验医学杂志,2015,30(03):151.[doi:10.3969/j.issn.1671-7414.2015.03.046]
　Study on Iron Metabolism in Type Diabetes Patients.Study on Iron Metabolism in Type 2 Diabetes Patients[J].Journal of Modern Laboratory Medicine,2015,30(02):151.[doi:10.3969/j.issn.1671-7414.2015.03.046]
[4]吴晓康,马超峰,余鹏博,等.2型糖尿病患者肠道菌群两种分子指纹图谱分析研究[J].现代检验医学杂志,2015,30(04):24.[doi:10.3969/j.issn.1671-7414.2015.04.006]
　WU Xiao-kang,MA Chao-feng,YU Peng-bo,et al.Analysis of Intestinal Microbiota of Type 2 Diabetes Patients of by Two Fingerprint Technologies[J].Journal of Modern Laboratory Medicine,2015,30(02):24.[doi:10.3969/j.issn.1671-7414.2015.04.006]
[5]张阳东a,陈洁b,楚瑞雪,等.2型糖尿病患者低密度脂蛋白水平及其受体基因表达水平研究[J].现代检验医学杂志,2015,30(05):97.[doi:10.3969/j.issn.1671-7414.2015.05.029]
　ZHANG Yang-donga,CHEN Jieb,CHU Rui-xue,et al.Study on Low-density Lipoprotein Levels and It’s Receptor Genes Expression Levels in Type 2 Diabetes Mellitus Patients[J].Journal of Modern Laboratory Medicine,2015,30(02):97.[doi:10.3969/j.issn.1671-7414.2015.05.029]
[6]王丹,王养维,李辉,等.2型糖尿病患者动脉粥样硬化病变与血清CTRP3和CTRP9水平的相关性研究[J].现代检验医学杂志,2015,30(06):20.[doi:10.3969/j.issn.1671-7414.2015.06.006]
　WANG Dan,WANG Yang-wei,LI Hui,et al.Correlation Research on Atherosclerotic Lesions with Serum CTRP3，CTRP9 Level in Patients with Type 2 Diabetic[J].Journal of Modern Laboratory Medicine,2015,30(02):20.[doi:10.3969/j.issn.1671-7414.2015.06.006]
[7]叶永红,陈月兰,詹禧奎,等.联合检测Ficolin-3,TRF及hs-CRP对2型糖尿病早期诊断价值[J].现代检验医学杂志,2016,31(04):74.[doi:10.3969/j.issn.16717-414.2016.04.019]
　YE Yong-hong,CHEN Yue-lan,ZHAN Xi-kui,et al.Early Diagnostic Value of Combined Detection of Ficolin-3, TRF and hs-CRP for Type 2 Diabetes[J].Journal of Modern Laboratory Medicine,2016,31(02):74.[doi:10.3969/j.issn.16717-414.2016.04.019]
[8]万淑君,王 成,王 静,等.2型糖尿病微血管并发症患者血清miR-16,miR-126和miR-221水平检测及临床意义[J].现代检验医学杂志,2016,31(05):9.[doi:10.3969/j.issn.1671-7414.2016.05.003]
　WAN Shu-jun,WANG Cheng,WANG Jing,et al.Study on Serum Levels of miR-16,miR-126 and miR-221 and Their Clinical Significance in Type 2 Diabetes Patients with or Without Microvascular Complications[J].Journal of Modern Laboratory Medicine,2016,31(02):9.[doi:10.3969/j.issn.1671-7414.2016.05.003]
[9]朱影明,许新强,周 强,等.广东地区2型糖尿病与抵抗素基因位点rs2161490和rs1423096多态性的相关性研究[J].现代检验医学杂志,2017,32(01):48.[doi:10.3969/j.issn.1671-7414.2017.01.014]
　ZHU Ying-ming,XU Xin-qiang,ZHOU Qiang,et al.Correlation Study between Resistin rs2161490 and rs1423096 and Type 2 Diabetes Mellitus[J].Journal of Modern Laboratory Medicine,2017,32(02):48.[doi:10.3969/j.issn.1671-7414.2017.01.014]
[10]郭宜晨,鲁亚静,钟伟传,等.2型糖尿病患者外周血miRNA表达谱差异研究[J].现代检验医学杂志,2018,33(06):5.[doi:10.3969/j.issn.1671-7414.2018.06.002]
　GUO Yi-chen,LU Ya-jing,ZHONG Wei-chuan,et al.Study on the Difference of Serum miRNA Expression Profile in Peripheral Blood of Patients with Type 2 Diabetes Mellitus[J].Journal of Modern Laboratory Medicine,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.06.002]

备注/Memo

备注/Memo:
基金资助:徐州市卫生局2011年医学科研项目(项目编号:XWJ2011073)。 作者简介:李全双(1982-),男,本科,主管技师,主要从事临床检验诊断工作,Tel:18652257126,E-mail:182001824@qq.com。 通讯作者:程 星,徐州市中心医院检验科,电话:18912007660。
更新日期/Last Update: 2015-03-20